Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29:9:20499361221095679.
doi: 10.1177/20499361221095679. eCollection 2022 Jan-Dec.

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis

Alpesh Amin  1 , Winnie W Nelson  2 , Jill Dreyfus  3 , Anny C Wong  3 , Iman Mohammadi  3 , Christie Teigland  3 , David N Dahdal  2 , Paul Feuerstadt  4
Affiliations

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis

Alpesh Amin et al. Ther Adv Infect Dis. .

Abstract

Objective: To describe mortality, healthcare resource utilization (HRU), and costs among Medicare beneficiaries with primary Clostridioides difficile infection (pCDI) or recurrent CDI (rCDI), with and without sepsis.

Methods: We conducted a retrospective observational study of 100% Medicare Fee-for-Service claims from adults aged ⩾ 65 years with ⩾1 CDI episode between 1 January 2009 and 31 December 2017. Patients were continuously enrolled in Medicare Parts A/B/D 12 months before and up to 12 months after pCDI. ICD-9/10 codes defined CDI using ⩾1 inpatient claim, or ⩾1 outpatient claim plus ⩾1 claim for CDI treatment. The pCDI episode ended after 14 days without a CDI claim. rCDI episodes started within 8 weeks from the end of a previous CDI episode. ICD-9/10 codes identified all-cause sepsis over 12 month follow-up.

Results: Of 497,489 CDI patients, 41.0% (N = 203,888) had sepsis; 57.7% with sepsis died versus 32.4% without sepsis. Among patients with pCDI only (N = 345,893) or ⩾1 rCDI (N = 151,596), 39.2% and 45.1% suffered sepsis, respectively. All-cause hospitalizations were frequent for all cohorts (range: 81-99%). Among patients who died, those with sepsis versus without had more-frequent intensive care unit (ICU) use (pCDI: 29% versus 15%; rCDI: 65% versus 34%), longer hospital stays (pCDI: 12 versus 10 days; rCDI: 12 versus 9 days), and higher per-patient-per-month costs (pCDI: $34,841 versus $22,753; rCDI: $42,269 versus $25,047). In both cohorts, sepsis patients who survived had higher total costs and all-cause HRU than those without sepsis. All p < 0.001 above.

Conclusions: Sepsis was common among Medicare beneficiaries with CDI. CDI patients with sepsis, especially after an rCDI, experienced higher mortality, HRU, and costs compared with those without sepsis.

Keywords: Clostridioides difficile; Clostridium difficile infection; Medicare; cost; healthcare resource utilization; recurrent CDI; sepsis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DD and WWN were employees of Ferring Pharmaceuticals at the time of the research and manuscript development. IM and CT are employees of Avalere Health. JD and AW were employees of Avalere Health at the time of the research and manuscript development. PF: Merck and Co.: Speakers Bureau; Ferring/Rebiotix: Consulting, Advisory Board; SERES Therapeutics: Advisory Board; Takeda Pharmaceuticals: Advisory Board. AA: PI or co-I of clinical trials sponsored by NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therpeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, Alexion. He has served as a speaker and/or consultant for BMS, Pfizer, BI, Portola, Sunovion, Mylan, Salix, Alexion, AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achogen LaJolla, Ferring, Seres, Millenium, HeartRite, Aseptiscope, Sprightly.

Figures

Figure 1.
Figure 1.
Study design: Definition of index CDI episode, including CDI claims (black bar), the 14-day CDI-claim-free period after last CDI claim (gray bar), and the 8-week period to identify rCDI (yellow bar).
Figure 2.
Figure 2.
Study attrition diagram.
Figure 3.
Figure 3.
Unadjusted mean healthcare costs (PPPM) by sepsis and mortality status**: 12-months postindex follow-up. Costs were inflation adjusted to 2018 $USD. **All p < 0.001. DME, durable medical equipment; ED, emergency department; PPPM: per-patient per-month; USD, US dollars.
See this image and copyright information in PMC

References

    1. Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract 2013; 26: 464–475. - PMC - PubMed
    1. Ma GK, Brensinger CM, Wu Q, et al.. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017; 167: 152–158. - PubMed
    1. Guh AY, Mu Y, Winston LG, et al.. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382: 1320–1330. - PMC - PubMed
    1. Magill SS, O’Leary E, Janelle SJ, et al.. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med 2018; 379: 1732–1744. - PMC - PubMed
    1. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009; 33(Suppl. 1): S33–S36. - PubMed